Idera to Release 2019 Second Quarter Results on August 8, 2019
August 06 2019 - 3:00PM
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a
clinical-stage biopharmaceutical company focused on the
development, and ultimately the commercialization, of therapeutic
drug candidates for both oncology and rare disease indications,
today announced that second quarter results for 2019 are expected
to be released on Thursday, August 8, 2019 before the opening of
the U.S. financial markets.
The company will host a conference call and live audio webcast
at 10:00 A.M. eastern time on the same day. During the
conference call, Idera management will also provide a corporate
update along with a question and answer session.
To participate in the conference call, please dial (844)
882-7837 (domestic) and (574) 990-9824 (international). The
webcast can be accessed live or in archived form in the “Investors”
section of the company’s website at www.iderapharma.com.
Archived versions will also be available on the Company’s website
after the event for 90 days.
About Idera
Pharmaceuticals
Harnessing the approach of the earliest researchers in
immunotherapy and the company’s vast experience in developing
proprietary immunomodulatory platforms, Idera’s TLR agonist
development program is focused on priming the immune system to play
a more powerful role in fighting cancer, ultimately increasing the
number of people who can benefit from immunotherapy. Idera also
continues to focus on the acquisition, development and ultimate
commercialization of drug candidates for both oncology and rare
disease indications characterized by small, well-defined patient
populations with serious unmet needs. To learn more about Idera,
visit www.iderapharma.com.
Idera Pharmaceuticals ContactRobert DoodySVP,
Investor Relations & Corporate CommunicationsPhone:
484-348-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2024 to May 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Idera Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles